• Transient Conformations Enable Ligand Binding in Adenine Rib

  2026-07-29

  Wu et al. revealed a transient unwound P1 helix conformation that facilitates ligand binding in the full-length adenine riboswitch, using real-time stopped-flow fluorescence and site-specific RNA labeling. This work provides unprecedented kinetic resolution of riboswitch structural transitions, refining our understanding of RNA-ligand interactions and guiding future RNA-protein interaction studies.

• Mitoxantrone: Applied Protocols and Resistance Solutions in

  2026-07-29

  Mitoxantrone remains a linchpin in anticancer research, but multidrug resistance—especially via the ABCG2 transporter—demands advanced workflows. Recent studies reveal how strategic co-therapies and optimized protocols can restore drug sensitivity, making Mitoxantrone-based experiments more predictive and translationally relevant.

• Enhancing In Vitro Evaluation of Anti-Cancer Drug Responses

  2026-07-28

  Schwartz's dissertation introduces a systematic comparison of in vitro drug response metrics, revealing that anti-cancer agents can distinctly affect cell proliferation and death. This nuanced approach offers researchers greater clarity in interpreting compound efficacy and supports more relevant preclinical modeling.

• Sulfachloropyridazine (SKU BA1082): Reliable Antibacterial R

  2026-07-28

  This article examines how Sulfachloropyridazine (SKU BA1082) addresses critical lab challenges in antimicrobial susceptibility testing, enzyme inhibition assays, and in vivo infection models. Drawing on peer-reviewed data and validated protocols, it guides researchers in leveraging this sulfonamide antibacterial agent for reproducible, sensitive, and mechanistically informative experiments.

• Gut-Brain Cholinergic Pathways in Microbiota-Mediated Seizur

  2026-07-27

  Jia et al. provide compelling evidence that Bacteroides fragilis reduces seizure susceptibility in pediatric refractory epilepsy by enhancing gut-brain cholinergic signaling. Their integration of preclinical and clinical approaches uncovers a mechanistic link between microbial modulation of acetylcholine neurotransmitter pathways and seizure suppression, offering a foundation for microbiota-targeted therapies.

• Sulfachloropyridazine Reshapes Microbiota in E. tenella-Infe

  2026-07-27

  The referenced study systematically evaluates the effects of sulfachloropyridazine, ethanamizuril, and their combination on cecal microbial and metabolite profiles in chickens infected with Eimeria tenella. By integrating 16S rRNA sequencing and LC-MS/MS metabolomics, the research clarifies drug- and combination-specific impacts on pathogenic and commensal bacteria, informing new strategies for monitoring drug efficacy and understanding microbiota-mediated responses during coccidiosis.

• CGP 55845 Hydrochloride in GABAB Receptor Antagonist Workflo

  2026-07-26

  CGP 55845 hydrochloride enables next-generation, astrocyte-focused GABAB receptor antagonist workflows, empowering precise modulation of neurotransmitter release in vitro. Discover how this APExBIO compound streamlines synaptic transmission research, supports advanced astrocyte-neuron circuit studies, and unlocks new troubleshooting strategies for high-fidelity neurotransmission assays.

• Marein Reverses ABCG2-Mediated Resistance to Mitoxantrone

  2026-07-25

  The referenced study uncovers marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of the ABCG2 transporter. This mechanism restores chemosensitivity in multidrug-resistant cancer cells to agents such as Mitoxantrone, providing a promising strategy to overcome a significant barrier in oncology research.

• Rotigotine Modulates Bladder Function in PD Model Rats

  2026-07-24

  This study systematically investigates rotigotine’s effects on lower urinary tract function in a 6-OHDA-induced rat model of Parkinson’s disease, revealing distinct impacts on intercontraction interval and voiding pressure depending on administration route. The findings advance understanding of dopaminergic modulation in PD-related bladder dysfunction and inform translational approaches for non-motor symptom research.

• T-5224 (C-Fos/AP-1 Inhibitor): A Paradigm Shift in Ferroptos

  2026-07-24

  Explore how T-5224, a potent C-Fos/AP-1 inhibitor, uniquely bridges inflammation modulation and ferroptosis induction. This in-depth analysis reveals mechanistic insights and practical assay guidance for advanced arthritis and cancer models.

• O-GlcNAc–HUWE1–TfR1 Axis Regulates Ferroptosis in Preeclamps

  2026-07-23

  This study elucidates a mechanistic pathway in which O-GlcNAc modification of HUWE1 facilitates ubiquitination-mediated degradation of the transferrin receptor TfR1, thereby limiting ferroptosis and supporting trophoblast syncytialization in preeclampsia. The findings highlight the therapeutic potential of modulating O-GlcNAcylation to address placental dysfunction in preeclampsia.

• Biotransformation Pathways of Sulfamonomethoxine in Granular

  2026-07-23

  This study elucidates the biotransformation mechanisms of Sulfamonomethoxine (SMM) in aerobic granular sludge systems, highlighting the predominance of biodegradation over adsorption and the pivotal role of hydroxylamine-mediated pathways. These findings advance the understanding of antibiotic removal in wastewater treatment and inform environmentally responsible applications of SMM.

• Doxycycline Hyclate as a Matrix Metalloproteinases Inhibitor

  2026-07-22

  Doxycycline hyclate is uniquely positioned for research into blood-brain barrier preservation and neurotoxicity, acting as a potent matrix metalloproteinases inhibitor. Recent experimental breakthroughs, including MMP-2/MMP-9-driven models, reveal its translational potential in both neurovascular and infection biology.

• Sulfachloropyridazine in Antibacterial Research: Protocols &

  2026-07-22

  Sulfachloropyridazine enables precise modulation of bacterial folate synthesis and the cecal microbiome, supporting advanced infection model studies and microbiota-metabolome profiling. This article translates recent breakthroughs into actionable protocols, troubleshooting tips, and comparative research advantages for both bench scientists and translational teams.

• SD 169: Dual-Action p38 MAPK Inhibition for Translational Re

  2026-07-21

  Explore how SD 169 (indole-5-carboxamide) leverages dual-action inhibition of p38 MAPK to advance research in inflammation, neuroregeneration, and type 1 diabetes. This article unpacks the mechanistic rationale, experimental evidence, and strategic recommendations for maximizing translational potential, building on recent structural insights.

456 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page